@article{fdi:010080935,
  title = {{D}elamanid resistance : update and clinical management},
  author = {{N}guyen, {T}. {V}. {A}. and {A}nthony, {R}. {M}. and {C}ao, {T}. {T}. {H}. and {B}anuls, {A}nne-{L}aure and {N}guyen, {V}. {A}. {T}. and {V}u, {D}. {H}. and {N}guyen, {N}. {V}. and {A}lffenaar, {J}. {W}. {C}.},
  editor = {},
  language = {{ENG}},
  abstract = {{D}elamanid, a-first-in-class bicyclic nitroimidazole, was recently approved for multidrug-resistant tuberculosis treatment. {P}itted against the hope for improving treatment outcomes is the threat of the rapid resistance emergence. {T}his review provides information on the mechanisms of action, resistance emergence, and drug susceptibility testing ({DST}) for delamanid. {D}elamanid resistance has already been reported in both in vitro experiments and clinical settings. {A}lthough mutations conferring delamanid resistance have been identified in fbi{A}, fbi{B}, fbi{C}, ddn, and fgd1 genes of {M}ycobacterium tuberculosis, knowledge about the molecular resistance mechanisms is limited, and there remains no standardized {DST} method. {T}he rapid acquisition of delamanid resistance emphasizes the need for optimal use of new drugs, the need for drug resistance surveillance, and a comprehensive understanding of drug resistance mechanisms. {F}urther studies are necessary to investigate genetic and phenotypic changes that determine clinically relevant delamanid resistance to help develop a rapid delamanid {DST}.},
  keywords = {delamanid ; drug resistance ; tuberculosis ; drug susceptibility testing ; pharmacokinetics ; pharmacodynamics},
  booktitle = {},
  journal = {{C}linical {I}nfectious {D}iseases},
  volume = {71},
  numero = {12},
  pages = {3252--3259},
  ISSN = {1058-4838},
  year = {2020},
  DOI = {10.1093/cid/ciaa755},
  URL = {https://www.documentation.ird.fr/hor/fdi:010080935},
}